A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorNovo Nordisk A/S
About this trial
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Eligibility criteria
Qualifiers
Male or female (sex at birth).
Age 18-55 years (both inclusive) at the time of signing informed consent.
Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m²) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.
Disqualifiers
Known or suspected hypersensitivity to study intervention(s) or related products.
Previous randomisation in this study.
History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
Trial design
Treatments tested in this trial
- NNC0721-8060
- Semaglutide
- Placebo
Treatment groups
142 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov